Who are Elbasvir Oral Granules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Viekira Pak ± ribavirin, sofosbubir/velpatasvir, D+Z, Elbasvir / Grazoprevir Oral Tablet [Zepatier], Sofosbuvir and Velpatasvir, Daclatasvir plus Asunaprevir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/elbasvir-oral-granules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Elbasvir Oral Granules — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Elbasvir Oral Granules (Elbasvir Oral Granules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NS5A inhibitor. Area: Infectious Disease.

phase 2 NS5A inhibitor NS5A protein Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Elbasvir Oral Granules (Elbasvir Oral Granules) — Merck Sharp & Dohme LLC. Inhibits NS5A protein of hepatitis C virus

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Elbasvir Oral Granules TARGET	Elbasvir Oral Granules	Merck Sharp & Dohme LLC	phase 2	NS5A inhibitor	NS5A protein
Viekira Pak ± ribavirin	Viekira Pak ± ribavirin	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein, HCV NS3/4A serine protease
sofosbubir/velpatasvir	sofosbubir/velpatasvir	Partners in Health	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein
D+Z	D+Z	Sequential Medicine Ltd	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
Elbasvir / Grazoprevir Oral Tablet [Zepatier]	Elbasvir / Grazoprevir Oral Tablet [Zepatier]	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS3/4A serine protease
Sofosbuvir and Velpatasvir	Sofosbuvir and Velpatasvir	Hannover Medical School	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein
Daclatasvir plus Asunaprevir	Daclatasvir plus Asunaprevir	Myeong Jun Song	marketed	Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	HCV NS5A protein and HCV NS3/4A serine protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NS5A inhibitor class)

Bristol-Myers Squibb · 2 drugs in this class
AbbVie · 1 drug in this class
Ferrer Internacional S.A. · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Elbasvir Oral Granules — Competitive Intelligence Brief. https://druglandscape.com/ci/elbasvir-oral-granules. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab